Co-Diagnostics entered into a material transfer agreement with ReadyGo Diagnostics in August 2026 to evaluate the compatibility of ReadyGo's sample collection and preparation technologies with Co-Diagnostics' Co-Dx PCR platform. Under this preliminary arrangement, ReadyGo will provide sampling materials for feasibility studies aimed at streamlining the sample-to-result workflow for decentralized testing environments. The agreement does not obligate either party to enter into future development or commercial arrangements, and there is no assurance that these evaluations will result in additional agreements. Co-Diagnostics operates in the molecular diagnostics industry, developing point-of-care PCR testing platforms.

Co-Diagnostics, Inc. announced that Brian Brown departed as Chief Financial Officer and Principal Accounting Officer effective September 2, 2026. Daniel Bohrer was appointed to serve as the new principal financial officer and principal accounting officer. In connection with this appointment, Mr. Bohrer's annual salary increased from $225,000 to $255,000. Co-Diagnostics operates in the healthcare diagnostics industry, developing molecular diagnostic tests.

Co-Diagnostics reported second quarter 2026 financial results with revenue of $0.17 million and a net loss of $6.3 million, or $1.46 per share, compared to a net loss of $7.7 million in the prior year period. The company completed a $3.0 million private placement priced at-the-market under Nasdaq rules to strengthen its balance sheet, which held $3.6 million in cash as of June 30, 2026. Operational milestones included submitting an FDA 510(k) application for the Co-Dx PCR Flu A/B & RSV test and appointing Wes Lindsey as Chief Scientific Officer. The company also expanded commercial outreach through a European trade mission and initiated clinical studies in India for its tuberculosis diagnostic platform. Co-Diagnostics operates in the molecular diagnostics industry, developing and manufacturing integrated testing platforms and assays.

Co-Diagnostics entered into an inducement agreement with existing warrant holders to exercise warrants for up to 1,702,362 shares at $1.571 per share, generating approximately $2.67 million in gross proceeds. In exchange, the company issued new warrants to purchase up to 3,404,724 shares at an exercise price of $1.56 per share. The transaction requires stockholder approval for the exercise of the new warrants and includes a lock-up preventing further equity issuances until August 31, 2026. Co-Diagnostics operates in the diagnostics industry.